RAS(ON) doublet maximizes pathway suppression and favorably modulates the TME of the ICB-refractory 3LL-ΔNRAS model. A, PD of elironrasib, daraxonrasib, and the RAS(ON) doublet in subcutaneous tumors shown as the relative change in pERK expression in tumor cells. Tumor-bearing mice were treated with a single dose of elironrasib at 30 mg/kg, daraxonrasib at 25 mg/kg, and the RAS(ON) doublet and tumors were collected at indicated time points. B, PROGENy MAPK and G2M score calculated based on bulk RNA-seq of whole tumors collected at 24 hours after 8 days of treatment. C, Quantification of as percentage of total cells in tumors collected at 24 hours after 8 days of treatment. D, Frequency of CD8 T cells, CD4 T cells, NK cells, granulocytic myeloid-derived suppressor cells (gMDSC; Ly6G+), M2 macrophages (CD11b+, F4/80+, CD206+) based on live, CD45+ cells, and H2Kb cell surface expression on tumor cells (large CD45−, periostin−) identified by multiparameter spectral flow cytometry in tumors collected at 24 hours after 8 days of treatment. E, Representative IHC images (scale bar, 100 μm) and (F) Quantification of CD4-, CD8-, and granzyme B–positive cells as percentage of total in tumors collected at 24 hours after 8 days of treatment. Values are plotted as mean ± SD. Each point is an individual tumor. Analysis was performed using one-way ANOVA. For all statistical analyses, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. po, orally; qd, every day.